Abstract 5905
Background
Developments in next generation sequencing (NGS) have revolutionized oncogenic biomarker detection, removing the limitations of single-nucleotide polymorphisms (SNPs) to allow for massive parallel sequencing to detect multiple oncogenic gene fusions. We believe NGS testing platforms are not uniform within the current solid tumor lab landscape, with NGS analysis capabilities ranging from SNPs only to SNPs and known gene fusions, potentially missing crucial biomarkers. The objective of this study was to determine the current NGS capability of solid tumor labs to detect unknown fusions.
Methods
This study used real-world clinical pathology solid tumor labs data from the United States, United Kingdom, France, Spain, Italy, and Germany that conduct NGS. The Diaceutics proprietary global database of more than 2500 labs was analysed across these markets in Q4 2018 to understand NGS testing capabilities currently available within the routine clinical lab setting.
Results
The results of the study are presented in the table. Of the 131 labs in the US performing NGS, only 50 were able to detect fusions. Of those 50 labs, 42 were restricted to using panels designed to detect specific known fusions. Only 8 labs in the US were able to detect unknown fusions. This pattern was reflected in labs surveyed in 5 other countries.Table: 1409P
Solid tumor labs: NGS panel use and gene fusion detection
Country | Number of solid tumor labs performing NGS | Number of labs that can detect fusions | Number of labs that can detect known fusions | Number of labs that can detect known and unknown fusions |
---|---|---|---|---|
US | 131 | 50 | 42 | 8 |
France | 39 | 11 | 7 | 4 |
Germany | 21 | 5 | 4 | 1 |
Spain | 23 | 4 | 4 | 0 |
Italy | 30 | 7 | 6 | 1 |
UK | 24 | 7 | 1 | 6 |
Conclusions
Labs are not well equipped to handle the pace of advancement in biomarker testing. While targeted treatments and companion diagnostics usher in a new age of precision medicine in cancer and extend survival times, many labs lack the technology needed to accurately identify emerging gene fusion biomarkers, especially unknown fusions. This results in both confusion among physicians regarding testing adequacy and missed opportunities for improved outcomes among patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Diaceutics.
Funding
Diaceutics.
Disclosure
S. Finucane: Full / Part-time employment: Diaceutics. S. Haridas: Shareholder / Stockholder / Stock options, Full / Part-time employment: Diaceutics. L. Handley: Full / Part-time employment: Diaceutics. J. Clark: Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Diaceutics. A. Jack: Shareholder / Stockholder / Stock options, Full / Part-time employment: Diaceutics. S. Munksted: Shareholder / Stockholder / Stock options, Full / Part-time employment: Diaceutics.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract